NFlection Therapeutics

NFlection Therapeutics, Inc. specializes in the development of novel therapies aimed at addressing rare dermatological disorders.NFlection Therapeutics specializes in the discovery and development of targeted topical therapies aimed at addressing rare disorders associated with the aberrant activation of the RAS pathway. The company's core product offerings include first-in-class MEK inhibitors, which are being developed for the treatment of conditions such as neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks like keratinocytic epidermal nevi and nevi sebacei. These novel therapies aim to provide patients with effective, localized treatment options that minimize systemic exposure while targeting the underlying molecular causes of their conditions.NFlection Therapeutics generates revenue through strategic partnerships and collaborations that facilitate the development and commercialization of its proprietary therapies. The company engages in transactions with healthcare providers and institutions, operating under a direct-to-consumer model for its flagship products once they are approved for market release. While specific pricing structures for their products are not disclosed, the company implements a pricing strategy reflective of the specialty pharmaceutical market, focusing on reimbursement from healthcare systems and insurance providers. The company aims to introduce new products targeting rare dermatological conditions in the coming years, expanding its market presence in North America and select European markets.

1. Series A

   Jun 9, 2020

   Amount

   $20M

   Investors

   Locked